Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)
Close on Nov 17, 2026Market cap $1.26BP/E –Yield –
Generate Biomedicines enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Generate Biomedicines's enterprise value was $1.27B on Nov 11, 2026.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.27B | – |
See a number that looks wrong?